- Home
- TOP vs KPTI Comparison
TOP vs KPTI Comparison
Compare TOP & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- KPTI
- Stock Information
- Founded
- TOP 2015
- KPTI 2008
- Country
- TOP Hong Kong
- KPTI United States
- Employees
- TOP N/A
- KPTI N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- TOP Finance
- KPTI Health Care
- Exchange
- TOP Nasdaq
- KPTI Nasdaq
- Market Cap
- TOP 44.1M
- KPTI 44.5M
- IPO Year
- TOP 2022
- KPTI 2013
- Fundamental
- Price
- TOP $1.24
- KPTI $4.49
- Analyst Decision
- TOP
- KPTI Buy
- Analyst Count
- TOP 0
- KPTI 6
- Target Price
- TOP N/A
- KPTI $48.50
- AVG Volume (30 Days)
- TOP 76.3K
- KPTI 90.3K
- Earning Date
- TOP 07-29-2025
- KPTI 08-05-2025
- Dividend Yield
- TOP N/A
- KPTI N/A
- EPS Growth
- TOP N/A
- KPTI N/A
- EPS
- TOP N/A
- KPTI N/A
- Revenue
- TOP $2,730,890.00
- KPTI $142,126,000.00
- Revenue This Year
- TOP N/A
- KPTI $2.34
- Revenue Next Year
- TOP N/A
- KPTI $13.81
- P/E Ratio
- TOP N/A
- KPTI N/A
- Revenue Growth
- TOP N/A
- KPTI 1.19
- 52 Week Low
- TOP $1.00
- KPTI $3.51
- 52 Week High
- TOP $1.94
- KPTI $17.40
- Technical
- Relative Strength Index (RSI)
- TOP 48.66
- KPTI 42.18
- Support Level
- TOP $1.20
- KPTI $4.06
- Resistance Level
- TOP $1.47
- KPTI $4.42
- Average True Range (ATR)
- TOP 0.08
- KPTI 0.36
- MACD
- TOP -0.01
- KPTI -0.03
- Stochastic Oscillator
- TOP 20.69
- KPTI 34.68
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.